Contribution of Next Sequencing Generation in Lung Cancer and Its Prognostic Implication DOI Open Access

Paula Lillo,

Juan Solchaga,

Irene Lázaro Rodríguez

et al.

Medical Research Archives, Journal Year: 2023, Volume and Issue: 11(10)

Published: Jan. 1, 2023

Lung cancer is one of the most commonly diagnosed cancers worldwide. It leading cause cancer-related deaths in both men and women. In 2020, there were an estimated 2.2 million new cases lung 1.8 due to disease. Historically, has been more common men, but gap closing. Smoking tobacco cancer. Survival rates for vary greatly depending on stage at diagnosis other factors. Overall, prognosis often poor, with a relatively low five-year survival rate compared some cancers. this work we aim show paths cancer, through study several mutations proteins, mostly detected by Next-generation sequencing (NGS) which significantly transformed our understanding providing high-throughput cost-effective methods analyzing genomic information. context NGS played crucial role advancing knowledge disease, improving treatment, guiding personalized medicine approaches. key points highlighting importance next-generation cancer: Comprehensive Genomic Profiling Identification Driver Mutations Stratification Patients Predicting Treatment Response Monitoring Disease Progression Clinical Trials Drug Development Early Detection Prognosis A large meta-analysis done, as well detailed 86 patients ANALIZA laboratory. sense frequently implicated tumor have analyzed, ALK, ROS1 EGFR, positions they occupy genes, addition programmed death ligand 1 (PD-L1), immune control protein, expressed activated cells cells, how its identification allows us direct treatment optimal way. summary, revolutionized field research clinical practice. By insights into landscape tumors, facilitates approaches, early detection, ongoing monitoring, ultimately improved patient outcomes.

Language: Английский

Conducting polymer composite-based biosensing materials for the diagnosis of lung cancer: A review DOI
Heru Agung Saputra, Khatun A. Jannath, Kwang Bok Kim

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 252, P. 126149 - 126149

Published: Aug. 13, 2023

Language: Английский

Citations

17
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study DOI Creative Commons
Roberto Serna‐Blasco,

Pilar Mediavilla-Medel,

Karla I. Medina

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: 204, P. 108550 - 108550

Published: April 24, 2025

In Spain, next-generation sequencing (NGS) is currently available in a limited number of specialized centers and remains inaccessible to significant proportion patients. The ATLAS study aims explore the tumor molecular profile beyond known EGFR mutations ALK translocations using NGS on biopsy samples. Patients with EGFR-sensitizing or were excluded. A total 455 patients advanced non-small cell lung cancer (NSCLC) enrolled from 22 Spanish hospitals. DNA RNA extracted formalin-fixed paraffin-embedded samples, libraries prepared Oncomine Focus Assay. Trialing app was used identify active clinical trials Spain. Mutations detected 65.7 % cases. Local pathology assessments druggable only 7.9 cases, while centralized testing increased this detection rate 25.9 %. most prevalent alteration KRAS G12C (53.6 %), followed by MET amplification (8.1 %) exon 14 skipping (7.3 %). Additionally, 34.5 had alterations matching trials, offering potential treatment opportunities. Women significantly higher probability harbouring (36 vs. 20.3 %, p < 0.001), including which more frequent females (22.6 10 common adenocarcinomas differentiation grade (p 0.001 = 0.049, respectively). Likewise, translocations, mutations, BRAF V600E, skipping, RET/ROS1 fusions mainly found whereas copy variations squamous carcinomas (28.6 15.1 %; 0.003) men (22 11.6 0.008). demonstrates utility comprehensive testing, detects clinically relevant than one-third may extend therapy options.

Language: Английский

Citations

0
Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain DOI Creative Commons

Sandra Zazo,

Sandra Pérez‐Buira,

Nerea Carvajal

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(3)

Published: Jan. 11, 2024

Abstract Objective This study aimed to describe the performance of a next‐generation sequencing (NGS) panel for detection precise genomic alterations in cancer Spanish clinical practice. The impact tumor characteristics was evaluated on informative NGS and actionable mutation rates. Materials Methods A cross‐sectional conducted at Fundación Jiménez Díaz University Hospital (May 2021–March 2022) where molecular diagnostic 537 Formalin‐Fixed Paraffin‐Embedded (FFPE) tissue samples diverse solid tumors (lung, colorectal, melanoma, gastrointestinal stromal, among others) performed using AVENIO Tumor Tissue Targeted Kit. descriptive analysis features all carried out. Multivariable logistic assess sample defined by results rate (for lung tumors), mutations only). Results 75.2% 75.3% samples, multivariable showed that surgical specimens are most likely provide than biopsies. Regarding mutational findings, 727 pathogenic, or variant unknown significance were found samples. Single nucleotide common alteration, both (85.3% 81.9% respectively). In tumors, it is more find from non‐smokers patients with adenocarcinoma, large cell, undifferentiated histologies. Conclusion largest cohort‐level Spain profile analyses biopsy different routine Our findings use routinely provides good rates can improve characterization identify greater number mutations.

Language: Английский

Citations

2
Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing DOI
Miguel García-Pardo, Inmaculada Aparicio,

Íñigo Martínez

et al.

Clinical Lung Cancer, Journal Year: 2023, Volume and Issue: 24(4), P. 366 - 370

Published: Feb. 9, 2023

Language: Английский

Citations

4
Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study DOI Open Access
Maximilian J. Hochmair, Angelika Terbuch, David Lang

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2586 - 2586

Published: July 19, 2024

This was a retrospective study of the profile and initial treatments adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients enrolled clinical trials. In total, 319 were planned ~1:1:1 ratio across StI:II:III. Most tested biomarkers programmed death ligand 1 (PD-L1; 58% expressing), Kirsten rat sarcoma virus (KRAS; 22% positive), epidermal growth factor receptor (EGFR; 18% positive). Of 115/98/106 StI/II/III patients, 82%/85%/36% underwent surgery, followed by systemic therapy 9%/45%/47% those [mostly chemotherapy (ChT)]. Unresected treated StIII received ChT + radiotherapy [43%; immune checkpoint inhibitors (ICIs) 39% those], ICI ± (35%), ChT-alone/radiotherapy-alone (22%). Treatment initiated median (interquartile range) 24 (7–39) days after histological confirmation, 55 (38–81) first medical visit. Based on exploratory analyses all newly any stage NSCLC 2018–2021 14 sites (N = 7846), 22%/10%/25%/43% had StI/II/III/IV. The total number not significantly different between pre-COVID-19 (2018–2019) study-specific COVID-19 (2020–2021) periods, while StI proportion increased (21% vs. 23%; p 0.012). Small differences noted treatments. conclusion, aligned guideline recommendations time which preceded era ICIs targeted therapies (neo)adjuvant setting.

Language: Английский

Citations

1
Quality of care assessment for non-small cell lung cancer patients: transforming routine care data into a continuous improvement system DOI Creative Commons
J. Sánchez,

B. Núñez-García,

Yago Garitaonaindía

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: 27(3), P. 1047 - 1061

Published: Aug. 16, 2024

The complexity of cancer care requires planning and analysis to achieve the highest level quality. We aim measure quality provided patients with non-small cell lung (NSCLC) using data contained in hospital's information systems, order establish a system continuous improvement. Retrospective observational cohort study conducted university hospital Spain, consecutively including all NSCLC treated between 2016 2020. A total 34 indicators were selected based on literature review clinical practice guideline recommendations, covering processes, timeliness, outcomes. Applying science methods, an algorithm, was set up integrate activity administrative extracted from Electronic Patient Record along registry. Through generated routine practice, it has been feasible reconstruct therapeutic trajectory automatically calculate algorithm guidelines. Process revealed high adherence outcome showed favorable survival rates compared previous data. Our proposes methodology take advantage sources, allowing feedback repeated measurement over time, developing tool understand metrics accordance evidence-based ultimately seeking improvement health care.

Language: Английский

Citations

1
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access DOI
F.A. Duarte, Pedro Nazareth Aguiar, Rodrigo Dienstmann

et al.

Expert Review of Pharmacoeconomics & Outcomes Research, Journal Year: 2023, Volume and Issue: 23(9), P. 981 - 987

Published: Sept. 26, 2023

ABSTRACTIntroduction Precision medicine is defined as personalized interventions fitted to patients' or tumors' characteristics. Patients diagnosed with different neoplasms have benefited from a therapeutic approach in terms of response and survival. However, several challenges must be addressed for precision oncology become global reality. Access genomic testing that allows biomarker identification main issue.Areas covered A nonsystematic literature review about inequities access molecular genetic testing, focusing on lung cancer the prominent example, was performed by group expert clinical oncologists.Expert opinion tests their matched treatments differ between regions world even among diverse populations same country. Socioeconomic characteristics are often strongly correlated this disparity. Furthermore, although cost determinant factor inequality, other issues been recognized. Advances education healthcare professionals, patient advocacy initiatives, building local laboratory workstreams, promoting favorable regulatory environment vital factors equal access.KEYWORDS: medicineinequitiesaccessoncologylung cancertarget therapy Article highlights Countless alterations recognized tumor drivers potential targets therapies.Lung successful example application Oncology.The costs innovative therapies against rising together broad such Next-Generation Sequencing (NGS).Geographic population distribution ethnic inequalities also barriers oncology.Global strategies improve oncology.Declaration interestThe authors no relevant affiliations financial involvement any organization entity interest conflict subject matter materials discussed manuscript. This includes employment, consultancies, honoraria, stock ownership options, testimony, grants patents received pending, royalties.Reviewer disclosuresPeer reviewers manuscript relationships disclose.Additional informationFundingThis paper not funded.

Language: Английский

Citations

3
Cytokine Profile in Lung Cancer Patients: Anti-tumor and Oncogenic Cytokines DOI Open Access
Freddy Elad Essogmo,

Zhilenkova Angelina V.,

Abah Moses Owoicho

et al.

Published: Aug. 23, 2023

Lung cancer accounts for the majority of cases. In recent years, checkpoint inhibitor immunotherapy (ICI) has emerged as a new treatment. A better understanding tumor microenvironment, or TMJ, immune system surrounding is needed. Cytokines are small proteins that carry messages between cells and known to play an important role in body's response inflammation infection. immunity lung cancer. It promotes growth (oncogenic cytokines) inhibits (anti-tumor by controlling signaling pathways growth, proliferation, metastasis, apoptosis. The relies heavily on cytokines. They can also be produced laboratory therapeutic use. Cytokine therapy helps stop kill cells. Interleukins interferons two types cytokines used treat This article begins addressing microenvironment (TMJ) its components review highlights functions various such IL, TGF TNF.

Language: Английский

Citations

1
Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity DOI Creative Commons
Yanmei Peng, Vinicius Ernani, Dan Liu

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(7), P. e28285 - e28285

Published: March 16, 2024

BackgroundROS1 rearrangements (ROS1+) define a distinct molecular subset of lung adenocarcinomas. ROS1 + tumors are known to occur more in never-smokers, but the frequency and outcome positivity by sex smoking intensity not clearly documented.Patients methodsThis patient cohort study included all never- (<100 cigarettes lifetime) light- (100 cigarettes-20 pack-years) smokers, sample heavy-smokers. rates were compared within beyond our study. Survival outcomes analyzed using Kaplan-Meier curves Cox proportional hazards models.ResultsOf 571 total patients, was detected 24 (4.2%): 6.4% men 3.0% women; 5.1% never-, 5.7% light-, 1.8% heavy-smokers (P=0.05). Among 209 stage IIIB-IV had much higher rate (11.1%) only than women (1.7%, P=0.004) study, also (0.4%–1.8%) 8 published studies (Ps = 0.0019–0.0001). ROS1+ similar between (9.3%) light-smokers (8.1%) significantly lower (1.2%, P=0.017), finding confirmed 6 0.041–0.0001). Overall survival patients better ROS1- (P=0.023) mainly due targeted therapy. who exhibited resistance crizotinib, follow-up treatment entrectinib lorlatinib showed remarkable benefits.ConclusionsThe women, light-smokers, pronounced patients. Newer-generation ALK/ROS1-targeted drugs efficacy crizotinib resistant These results, when validated, could assist efficiently accruing

Language: Английский

Citations

0
Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil DOI Creative Commons
Aline Fusco Fares,

Pedro H. Martinez,

Pedro H. Farina

et al.

JTO Clinical and Research Reports, Journal Year: 2022, Volume and Issue: 3(10), P. 100402 - 100402

Published: Aug. 30, 2022

Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists' attitudes toward CGP a scenario where sponsored funding was available.We designed an online survey assessing use and treating physicians' confidence, composed three self-confidence domains, which are as follows: confidence interpreting results, oncogenic-driven LUAD, managing tyrosine kinase inhibitor adverse events. The distributed oncologists who treat cancer Brazil. Comparisons between groups were performed using the chi-square or Fisher's exact test. Univariable multivariable (adjusted OR) analyses performed.Among 104 respondents patients with cancer, 55% from Southeast region, 28% had high clinical load, 33% in-house molecular testing. More than half (51%) participants request systematically stage IV LUAD. As provider 67% stated being confident all domains: 76% CGP, 84% 81% Providers' associated requesting LUAD (p = 0.013). After controlling variables interest, systematic revealed significant association provider's OR 0.35, p 0.028, 95% CI: 0.14-0.84). major challenge properly long turnaround time fear delays.Even though Brazil is fully sponsored, only our it.. Requesting providers' confidence. Improving access promoting awareness utility necessary increase better inform decisions.

Language: Английский

Citations

1